Practice Management News

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

The FDA granted fast track designation to brepocitinib for the treatment of nonanterior noninfectious uveitis, according to a press release from Priovant Therapeutics.

Nipocalimab resulted in more live births at 32 weeks’ gestation or later without fetal anemia or intrauterine transfusion for pregnancies at risk for early-onset severe hemolytic disease of the fetus and newborn, researchers reported.

Physicians can use social media to combat medical misinformation that spreads through it, according to a speaker at the Osteopathic Medical Education Conference.

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, shouts out key stories in the September issue, including an in-depth feature about what young rheumatologists expect from the field.

This month’s roundtable features a group of budding rheumatologists, still in training, who share their thoughts on how to sort out, define and achieve their goals in the workplace.

Many rheumatologists working today have navigated the specialty from the era of deeply flawed treatments like gold, through epoch-defining shifts brought on by biologics, biosimilars and, most recently, the unexpected crisis of COVID-19.

Time in the market is far more important than timing the market. Long-term investors will utilize both the strategies of dollar cost averaging and lump sum investing to reach their investment goals.

The FDA approved AstraZeneca’s Fasenra for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA, according to a company press release.

A novel remote monitoring app could help patients provide real-time information about their disease — including flares and other health care visits — to their rheumatologist in the long durations between visits.